Biosimilarity FDA perspective バイオシミラー

定価 約27,、現在アマゾンの最安値が約17,です。
バイオシミラー薬・FDAについての洋書のハードカバー本です。

●状態：表紙の角がやや擦れていますが、中身は一部のみ読んだほぼ新品です。
●ヤケ：なし
●折り目：なし
●書き込み：なし
●その他、注意事項：
中古品ということをご理解の上ご検討ください。宜しくお願いします
商品の情報
カテゴリー
本・音楽・ゲーム > 本 > 洋書
商品の状態
未使用に近い
7150円Biosimilarity FDA perspective バイオシミラー本・音楽・ゲーム本The Top 5 Biosimilar Articles for the Week of June 26

宅配便配送 Biosimilarity FDA perspective バイオシミラー 洋書


Biosimilarity: The FDA Perspective


休日 Biosimilarity FDA perspective バイオシミラー savingssafari.com


Biosimilarity: The FDA Perspective See more 1st Edition1st Edition


休日 Biosimilarity FDA perspective バイオシミラー savingssafari.com


An FDA perspective on the assessment of proposed biosimilar


休日 Biosimilarity FDA perspective バイオシミラー savingssafari.com


宅配便配送 Biosimilarity FDA perspective バイオシミラー 洋書


宅配便配送 Biosimilarity FDA perspective バイオシミラー 洋書


休日 Biosimilarity FDA perspective バイオシミラー savingssafari.com


Novartis, Roche, and Pfizer respond to FDA Biosimilar Action Plan


The Top 5 Biosimilar Articles for the Week of June 26


宅配便配送 Biosimilarity FDA perspective バイオシミラー 洋書


The Biosimilar Market: What You Need to Know - Retina Today


Biosimilar Clinical Trials and US FDA Guidance | ProRelix Research


Pharmaceutics | Free Full-Text | The Biosimilar Landscape: An


The Journey from Biologic to Biosimilar—A Clinical Perspective - ACRP


The Basics of Biosimilars


Pharmacodynamic Biomarkers: Their Role in Biosimilar Product


Biosimilar Clinical Trials and US FDA Guidance | ProRelix Research


Provider and Patient Knowledge Gaps on Biosimilars: Insights From


Biosimilar Clinical Trials and US FDA Guidance by ProRelix Info


FDA Perspectives on Biosimilar BLA-Manufacturing (28of33) Quality – Oct.  16-17, 2019


Tentative Biosimilar Approvals A Consideration for the US FDA


The U.S. Biosimilar Pathway: Policy Precedes Science


Functional Biosimilarity to Replace Clinical Efficacy Testing of


Key Considerations in Biosimilars Development


Biosimilars in Developed Economies: Overview, Status, and


FDA approval of biosimilars in the United States | Download Table


Biosimilars are here to help, really - Prime Therapeutics LLC


Biosimilars


Biosimilars 2022 Year in Review


The evolution of biosimilars in the US


FDA Releases Biosimilars Guidelines to Little Fanfare


Biosimilar or Not: Physicochemical and Biological Characterization


Revisiting Interchangeability to Realize the Benefit of Biosimilars


Safety, Immunogenicity and Interchangeability of Biosimilar


Biosimilarity assessment of biosimilar therapeutic monoclonal


From our perspective: Biosimilar product labeling | FDA


Frontiers | Switching Among Biosimilars: A Review of Clinical Evidence